{"id":1018616,"date":"2026-11-09T07:22:30","date_gmt":"2026-11-09T12:22:30","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-announces-closing-of-21-0-million-public-offering-with-24-contribution-from-the-board-chairman\/"},"modified":"2026-11-09T07:22:30","modified_gmt":"2026-11-09T12:22:30","slug":"annovis-announces-closing-of-21-0-million-public-offering-with-24-contribution-from-the-board-chairman","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-announces-closing-of-21-0-million-public-offering-with-24-contribution-from-the-board-chairman\/","title":{"rendered":"Annovis Announces Closing of $21.0 Million Public Offering with 24% Contribution from the Board Chairman"},"content":{"rendered":"<div class=\"mw_release\">\n<ul>\n<li>\n          <em>Annovis Chairman of the Board invested $5.0 million as part of the underwritten public offering\u00a0<\/em>\n        <\/li>\n<li>\n          <em>Company expects cash to fund operations through the pivotal Phase 3 Alzheimer\u2019s data readout in March 2027<\/p>\n<p><\/em>\n        <\/li>\n<\/ul>\n<p>MALVERN, Pa., Nov.  09, 2026  (GLOBE NEWSWIRE) &#8212; Annovis Bio, Inc. (NYSE: ANVS) (\u201cAnnovis\u201d or the \u201cCompany\u201d), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer\u2019s disease (AD) and Parkinson\u2019s disease (PD), today announced that its Chairman participated in the underwritten public offering and contributed $5.00 million, or approximately 24% of the $21.0 million offering, which closed on November 6, 2026.<\/p>\n<p>\u201cA significant contribution like this shows strong faith and confidence in our drug and its development,\u201d said Maria Maccecchini, Ph.D., Founder, President and CEO of Annovis. \u201cWe have spent years building this program with the interests of our shareholders and patients in mind. This financing allows us to reach the data readout of our pivotal Phase 3 study of buntanetap in early AD in March 2027, a milestone our entire team is excited about and fully committed to delivering.\u201d<\/p>\n<p>The offering generated approximately $21.0 million, excluding any proceeds from the exercise of the accompanying warrants. Together with existing cash, the net proceeds are expected to fund operations without interruption through the top-line data readout from the pivotal Phase 3 AD study and the continued clinical development of buntanetap in AD and PD.<\/p>\n<p>Full terms of the offering can be found in the Company\u2019s <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fcDONSXJE_besdHRSJ7NKiLmL1PgLfGjW-hbfmg-7E7_aYxsnNsDcU6VUdYYGYgPGJZ9CNYIS-K_3_V-bwVOyVIr3qf-lj8A2KmzlCkfWCg=\" rel=\"nofollow\" target=\"_blank\">SEC filings<\/a>.<\/p>\n<p>\n        <strong>About Annovis<\/strong><br \/>\n        <br \/>Headquartered in Malvern, Pennsylvania, Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer&#8217;s disease (AD) and Parkinson&#8217;s disease (PD). The Company&#8217;s lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1RL5xv92lq-sSShjK9XA8l8AfFGvS-3q-nT9dAgB1eQ_CdWQniBXYqMwSmsgmW8JZfMoUb7ldKnC-ivCkrN9m9U9crdo9ZNKlmmgTTAS1o4iC1YoedYuaoXg-bvKOY3jRSJRUrScoRsIxkNXDO5_839LBdoNITUEHy8WVH9xC9MkRQ-euLKWRWBbFvK4wgepb6er94HCoDnPgq0aWdtWdGAEkomHMWHqWYC83G_L0gJ2gAX3OdCbAcyCxE9oyztvoIvU-GtG9HKa9tU-WFTxxw==\" rel=\"nofollow\" target=\"_blank\">www.annovisbio.com<\/a>\u00a0and follow us on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_uJr_VQUJDv3bId_ujEStmAIYX3poxuRG25bJG4DlaZuWvinAUTTZQUmtw9kgkevRKSDTLdoijf9xwlD2q86asg2zPHjRfoEbp2y8g_TxvmHBa8SUSB7quaeyqim1ZIZiFc1JxfHyAGq6vqDWQ1b-ozS7Z8aelmya6zpBBUfcyIJkSiEHZB_r4FXL6ERjVjE0CnuLH6O22-toXz_x3MonyDDQSmHI0yMKPxFJ3FYu4QA6WgwWDKfKIzUWQLMUYxkICVU5fCxoobecIMKMmn9RNHNNvLWU4JllgCwlKXPWX3LDP3349fD-1LJULVXbyCf\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>,\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=80ueudwFr0Lm1A_JJ-YTQ99TJcu0dKN3Vqqs7Ylhp2pRSHfbFWS74ThpI9Z_QZI3kVEDHoUOyhIuQWgpa0ihErXzJKs09vPyix5ddMfwXhg9dPJ4EX7peK3WM6DvZ_uEZ8GWhE8r2E8M8DIEYdq7j9HX4AfbZQmNbXkQv3NOT5GKaHRY7AVsr7JHQMDoojnBykYj0Qj5eCk6rAOIzHEl6eZz1mHBbCgh9XnMKON7JZnV_-wl96Nl8GIP9Ugt_dNP\" rel=\"nofollow\" target=\"_blank\">YouTube<\/a>, and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=XckxyZDU1eMG99qOqspqGwz4PQ2mmsuGF86NpaQzfSbwtsQaKx6EsrO02__RcNy3Rf4PCwEgnsO86iAOk4SME0gGUpNzOefxv5j12qCM39ZzyVaEMvzGziIeqG_FmMvFm8CNV7_DrXQZh5pA-mpAwPM2bxLM2SungI2s6Iv-CqVc_vyERGo1uJ3WTDr0uovqt-8NkwXnb3_KVeYWpAuicw==\" rel=\"nofollow\" target=\"_blank\">X<\/a>.<\/p>\n<p>\n        <strong>Investor Alerts<\/strong><br \/>\n        <br \/>Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1SviFdPIK8j1VSlppiKhqnU8GisEsq7AQ3yxFV5ms5izUa1FG56txlqXLp3AnijIhcgJaNHbdja2_6RJSQoOv7CyIfPUrDWYcPEbCVHbZlSBpOuwMP6Y_JnlbtcyMz0GAPmEof-w26c2GYPPuGmSBWDFDhRHi805bifzW3Ji3Hr9FRmwYDpfBGi6tt6o3H3RiLYYsKuQL08zoEUvqOttM5SS4YSYzDun1Tzbv21X8V2Ttzh2JEnWP_5I4PeFDZVhJv49x2gOUqYhGZ588XnbissO2GM6Fs6VfNVzniW6f_IPKd1qvmGqnaXk87qxTBUCr5EgJeGNFJyoW3N_KY_dCheQsGVoeVwbVUFgFb6KkFM=\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.annovisbio.com\/email-alerts<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. Actual results may differ due to various risks and uncertainties, including those outlined in the Company\u2019s SEC filings under \u201cRisk Factors\u201d in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.<\/p>\n<p>\n        <strong>Contact Information:<\/strong><br \/>\n        <br \/>Annovis Bio Inc.<br \/>101 Lindenwood Drive<br \/>Suite 225<br \/>Malvern, PA 19355<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1RL5xv92lq-sSShjK9XA8vFGlNzTao-lRM2xGg68XtYM--Pu4TRyrF6ntJNh8kxXMMLkkfpC5o6HM8IlvkopOhWseICWWJv_BtqlNGKMt0IT8siSejpe5lazkOsGYElKiqmVonvYgTLKO6ZseWbf2tQ6gX3yZCINGwaLgxLNqsZkoAblz2MdpaLGH_onLQa86RquMrwIxZIxWTEIaG24hoTBfTmOnSUujBUHk1eGgSNTX6LPGj0sE6b_VOO1JL5AT4a4KWr3mMl5oiFEcjr_SA==\" rel=\"nofollow\" target=\"_blank\">www.annovisbio.com<\/a><\/p>\n<p>\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Alexander Morin, Ph.D.<br \/>Director, Strategic Communications<br \/>Annovis Bio<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YqfhCV2CwtwEAC_KqY54cxRuHAoP6MdUc_qxUwQL7EopN885xxmM5NdMxxk8ILU6kuWrtgz-hT8qK3cM3ltLhCrlTvBZGgRnu09zzTKjtz0=\" rel=\"nofollow\" target=\"_blank\">ir@annovisbio.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3Mjk5NSM3OTUyOTAxIzIxOTQ4NTA=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NzA2NTllOGEtZDM0MS00Y2MxLThjYjMtZjU4Yjc1ZDJiMGQ1LTEyMDY0MDMtMjAyNi0xMS0wOS1lbg==\/tiny\/Annovis-Bio-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Annovis Chairman of the Board invested $5.0 million as part of the underwritten public offering\u00a0 Company expects cash to fund operations through the pivotal Phase 3 Alzheimer\u2019s data readout in March 2027 MALVERN, Pa., Nov. 09, 2026 (GLOBE NEWSWIRE) &#8212; Annovis Bio, Inc. (NYSE: ANVS) (\u201cAnnovis\u201d or the \u201cCompany\u201d), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer\u2019s disease (AD) and Parkinson\u2019s disease (PD), today announced that its Chairman participated in the underwritten public offering and contributed $5.00 million, or approximately 24% of the $21.0 million offering, which closed on November 6, 2026. \u201cA significant contribution like this shows strong faith and confidence in our drug and its development,\u201d said Maria &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-announces-closing-of-21-0-million-public-offering-with-24-contribution-from-the-board-chairman\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Annovis Announces Closing of $21.0 Million Public Offering with 24% Contribution from the Board Chairman&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1018616","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Annovis Announces Closing of $21.0 Million Public Offering with 24% Contribution from the Board Chairman - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-announces-closing-of-21-0-million-public-offering-with-24-contribution-from-the-board-chairman\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Annovis Announces Closing of $21.0 Million Public Offering with 24% Contribution from the Board Chairman - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Annovis Chairman of the Board invested $5.0 million as part of the underwritten public offering\u00a0 Company expects cash to fund operations through the pivotal Phase 3 Alzheimer\u2019s data readout in March 2027 MALVERN, Pa., Nov. 09, 2026 (GLOBE NEWSWIRE) &#8212; Annovis Bio, Inc. (NYSE: ANVS) (\u201cAnnovis\u201d or the \u201cCompany\u201d), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer\u2019s disease (AD) and Parkinson\u2019s disease (PD), today announced that its Chairman participated in the underwritten public offering and contributed $5.00 million, or approximately 24% of the $21.0 million offering, which closed on November 6, 2026. \u201cA significant contribution like this shows strong faith and confidence in our drug and its development,\u201d said Maria &hellip; Continue reading &quot;Annovis Announces Closing of $21.0 Million Public Offering with 24% Contribution from the Board Chairman&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-announces-closing-of-21-0-million-public-offering-with-24-contribution-from-the-board-chairman\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-09T12:22:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3Mjk5NSM3OTUyOTAxIzIxOTQ4NTA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-announces-closing-of-21-0-million-public-offering-with-24-contribution-from-the-board-chairman\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-announces-closing-of-21-0-million-public-offering-with-24-contribution-from-the-board-chairman\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Annovis Announces Closing of $21.0 Million Public Offering with 24% Contribution from the Board Chairman\",\"datePublished\":\"2026-11-09T12:22:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-announces-closing-of-21-0-million-public-offering-with-24-contribution-from-the-board-chairman\\\/\"},\"wordCount\":481,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-announces-closing-of-21-0-million-public-offering-with-24-contribution-from-the-board-chairman\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3Mjk5NSM3OTUyOTAxIzIxOTQ4NTA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-announces-closing-of-21-0-million-public-offering-with-24-contribution-from-the-board-chairman\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-announces-closing-of-21-0-million-public-offering-with-24-contribution-from-the-board-chairman\\\/\",\"name\":\"Annovis Announces Closing of $21.0 Million Public Offering with 24% Contribution from the Board Chairman - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-announces-closing-of-21-0-million-public-offering-with-24-contribution-from-the-board-chairman\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-announces-closing-of-21-0-million-public-offering-with-24-contribution-from-the-board-chairman\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3Mjk5NSM3OTUyOTAxIzIxOTQ4NTA=\",\"datePublished\":\"2026-11-09T12:22:30+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-announces-closing-of-21-0-million-public-offering-with-24-contribution-from-the-board-chairman\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-announces-closing-of-21-0-million-public-offering-with-24-contribution-from-the-board-chairman\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-announces-closing-of-21-0-million-public-offering-with-24-contribution-from-the-board-chairman\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3Mjk5NSM3OTUyOTAxIzIxOTQ4NTA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3Mjk5NSM3OTUyOTAxIzIxOTQ4NTA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-announces-closing-of-21-0-million-public-offering-with-24-contribution-from-the-board-chairman\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Annovis Announces Closing of $21.0 Million Public Offering with 24% Contribution from the Board Chairman\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Annovis Announces Closing of $21.0 Million Public Offering with 24% Contribution from the Board Chairman - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-announces-closing-of-21-0-million-public-offering-with-24-contribution-from-the-board-chairman\/","og_locale":"en_US","og_type":"article","og_title":"Annovis Announces Closing of $21.0 Million Public Offering with 24% Contribution from the Board Chairman - Market Newsdesk","og_description":"Annovis Chairman of the Board invested $5.0 million as part of the underwritten public offering\u00a0 Company expects cash to fund operations through the pivotal Phase 3 Alzheimer\u2019s data readout in March 2027 MALVERN, Pa., Nov. 09, 2026 (GLOBE NEWSWIRE) &#8212; Annovis Bio, Inc. (NYSE: ANVS) (\u201cAnnovis\u201d or the \u201cCompany\u201d), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer\u2019s disease (AD) and Parkinson\u2019s disease (PD), today announced that its Chairman participated in the underwritten public offering and contributed $5.00 million, or approximately 24% of the $21.0 million offering, which closed on November 6, 2026. \u201cA significant contribution like this shows strong faith and confidence in our drug and its development,\u201d said Maria &hellip; Continue reading \"Annovis Announces Closing of $21.0 Million Public Offering with 24% Contribution from the Board Chairman\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-announces-closing-of-21-0-million-public-offering-with-24-contribution-from-the-board-chairman\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-09T12:22:30+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3Mjk5NSM3OTUyOTAxIzIxOTQ4NTA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-announces-closing-of-21-0-million-public-offering-with-24-contribution-from-the-board-chairman\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-announces-closing-of-21-0-million-public-offering-with-24-contribution-from-the-board-chairman\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Annovis Announces Closing of $21.0 Million Public Offering with 24% Contribution from the Board Chairman","datePublished":"2026-11-09T12:22:30+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-announces-closing-of-21-0-million-public-offering-with-24-contribution-from-the-board-chairman\/"},"wordCount":481,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-announces-closing-of-21-0-million-public-offering-with-24-contribution-from-the-board-chairman\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3Mjk5NSM3OTUyOTAxIzIxOTQ4NTA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-announces-closing-of-21-0-million-public-offering-with-24-contribution-from-the-board-chairman\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-announces-closing-of-21-0-million-public-offering-with-24-contribution-from-the-board-chairman\/","name":"Annovis Announces Closing of $21.0 Million Public Offering with 24% Contribution from the Board Chairman - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-announces-closing-of-21-0-million-public-offering-with-24-contribution-from-the-board-chairman\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-announces-closing-of-21-0-million-public-offering-with-24-contribution-from-the-board-chairman\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3Mjk5NSM3OTUyOTAxIzIxOTQ4NTA=","datePublished":"2026-11-09T12:22:30+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-announces-closing-of-21-0-million-public-offering-with-24-contribution-from-the-board-chairman\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/annovis-announces-closing-of-21-0-million-public-offering-with-24-contribution-from-the-board-chairman\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-announces-closing-of-21-0-million-public-offering-with-24-contribution-from-the-board-chairman\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3Mjk5NSM3OTUyOTAxIzIxOTQ4NTA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3Mjk5NSM3OTUyOTAxIzIxOTQ4NTA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-announces-closing-of-21-0-million-public-offering-with-24-contribution-from-the-board-chairman\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Annovis Announces Closing of $21.0 Million Public Offering with 24% Contribution from the Board Chairman"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1018616","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1018616"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1018616\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1018616"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1018616"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1018616"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}